Correspondence: Does midlife obesity really lower dementia risk?

Robinson, Philip C. and Merriman, Tony R. (2015) Correspondence: Does midlife obesity really lower dementia risk?. Lancet Diabetes & Endocrinology, 3 7: 501-501. doi:10.1016/s2213-8587(15)00218-1


Author Robinson, Philip C.
Merriman, Tony R.
Title Correspondence: Does midlife obesity really lower dementia risk?
Journal name Lancet Diabetes & Endocrinology   Check publisher's open access policy
ISSN 2213-8587
2213-8595
Publication date 2015-07
Sub-type Letter to editor, brief commentary or brief communication
DOI 10.1016/s2213-8587(15)00218-1
Open Access Status Not Open Access
Volume 3
Issue 7
Start page 501
End page 501
Total pages 1
Place of publication London, United Kingdom
Publisher The Lancet Publishing Group
Collection year 2016
Language eng
Formatted abstract
We read with interest the paper published by Qizilbash and colleagues.1 in which they reported a positive association between underweight and dementia. Not considered by the authors was the possibility that the association might be at least partly mediated by serum urate. BMI and serum urate are positively correlated and mendelian randomisation has provided evidence that obesity is causally involved in raising serum urate concentrations, causing hyperuricaemia.2 Hyperuricaemia has been associated with protection from Alzheimer's disease and Parkinson's disease in some observational studies.3 and 4 An intervention study was recently completed showing that inosine can raise urate concentration in patients with Parkinson's disease.5 In addition, variants in SLC2A9, which explain 3% of variance in urate concentrations, have been associated with Alzheimer's disease in genetic studies.6 It could be very informative for Qizilbash and colleagues to adjust their data by serum urate concentration, if available.

Urate is an extracellular antioxidant but an intracellular pro-oxidant, and the antioxidant action of urate in the brain is the most prominent theory as to why elevated serum urate is protective of neurodegenerative disease. Further mendelian randomisation and intervention studies will likely shed light on this interesting observation and enable us to answer the question of whether urate-lowering interventions for hyperuricaemia management increase the risk of progression to neurodegenerative disease.

PCR has received grants and speaking fees from AstraZeneca, and speaking and consulting fees from Menarini. TRM declares no competing interests.
Q-Index Code CX
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Letter to editor, brief commentary or brief communication
Collections: Non HERDC
Queensland Brain Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Mon, 04 Apr 2016, 16:41:11 EST by Susan Day on behalf of Queensland Brain Institute